Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-23-086092
Filing Date
2023-11-13
Accepted
2023-11-13 16:05:51
Documents
90
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0923_immucell.htm   iXBRL 10-Q 1177040
2 CERTIFICATION f10q0923ex31_immucell.htm EX-31 9767
3 CERTIFICATION f10q0923ex32_immucell.htm EX-32 4846
  Complete submission text file 0001213900-23-086092.txt   7302875

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE iccc-20230930.xsd EX-101.SCH 74532
5 XBRL CALCULATION FILE iccc-20230930_cal.xml EX-101.CAL 39139
6 XBRL DEFINITION FILE iccc-20230930_def.xml EX-101.DEF 327756
7 XBRL LABEL FILE iccc-20230930_lab.xml EX-101.LAB 628495
8 XBRL PRESENTATION FILE iccc-20230930_pre.xml EX-101.PRE 345908
84 EXTRACTED XBRL INSTANCE DOCUMENT f10q0923_immucell_htm.xml XML 1128347
Mailing Address 56 EVERGREEN DRIVE PORTLAND ME 04103
Business Address 56 EVERGREEN DR PORTLAND ME 04103 2078782770
IMMUCELL CORP /DE/ (Filer) CIK: 0000811641 (see all company filings)

EIN.: 010382980 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-12934 | Film No.: 231398606
SIC: 2835 In Vitro & In Vivo Diagnostic Substances